This is a Scorecard review, revisiting a past LF0 research call against what actually happened.
Ticker: RRGB Rating: Sell Published: 2026-08-19 Checkpoint: 2026-09-19 Entry price: $9.51 Latest price: $7.05 as of 2026-09-18 Stock return since entry: -25.9% Signal return: +25.9% Verdict: Correct so far
This is the 1-month checkpoint for this call. LF0 publishes monthly Scorecard updates through month 6, using the closest available daily close on or before the checkpoint date.
Read the original LF0 analysis
What I Said
I rated RRGB a Sell because I thought the balance sheet and cash flow problem still outweighed the revenue rebound. My original case leaned on the fact that Q1 2026 revenue of $378.3M and EBITDA of $20.9M were better, but still not enough to offset $502.4M of debt, only $22M of operating cash flow, and a 0.71x current ratio. I also said I would need quarterly EBITDA above $25M and a refinancing solution before I could get more constructive.
Peer Comparison
| Company | Return Since Entry |
|---|---|
| RRGB (this call) | -25.9% |
| BLMN | -23.9% |
| PTLO | -23.6% |
| SHAK | -25.1% |
| TXRH | -17.1% |
| WEN | -23.9% |
Why It’s Working (Or Not)
So far, following my Sell would have earned about 25.9%, which means the call has worked in the direction I expected. The stock has fallen while the peer group has also been broadly lower, so RRGB has not been an isolated move, but the key point is that my bearish thesis has not been contradicted by the price action. What has been validated is the idea that the market was still discounting the leverage and cash flow overhang rather than rewarding the modest operating improvement. What has not yet been fully tested is the refinancing piece, so I cannot claim the balance-sheet risk is solved just because the stock moved down.
What Could Still Prove Me Wrong
What could still prove me wrong is a sustained improvement in the operating numbers I flagged: quarterly EBITDA moving above $25M and staying there, with levered free cash flow turning positive. If management secures refinancing on reasonable terms and net debt/EBITDA moves materially below the 6.0x level I cited, that would weaken the core of my Sell case. If instead EBITDA slips back or refinancing comes back punitive, that would reinforce the original thesis rather than overturn it.
The August 2026 Cohort
Other directional calls published the same month:
| Ticker | Rating | Entry | Latest | Stock Return | Signal Return | Verdict |
|---|---|---|---|---|---|---|
| SDGR | Sell | $17.40 | $29.02 | +66.8% | -66.8% | Incorrect so far |
| WGS | Sell | $77.88 | $101.10 | +29.8% | -29.8% | Incorrect so far |
| ALT | Sell | $3.15 | $3.25 | +3.2% | -3.2% | Incorrect so far |
| VNOM | Sell | $41.67 | $42.27 | +1.4% | -1.4% | Incorrect so far |
| AES | Sell | $14.71 | $14.83 | +0.8% | -0.8% | Incorrect so far |
| SPHR | Sell | $147.34 | $145.19 | -1.5% | +1.5% | Correct so far |
| STXS | Sell | $1.39 | $1.33 | -4.3% | +4.3% | Correct so far |
| NNDM | Sell | $1.65 | $1.57 | -4.8% | +4.8% | Correct so far |
| LHX | Sell | $260.92 | $247.29 | -5.2% | +5.2% | Correct so far |
| BA | Sell | $210.46 | $198.20 | -5.8% | +5.8% | Correct so far |
| ADTN | Sell | $7.76 | $7.20 | -7.2% | +7.2% | Correct so far |
| GTN | Sell | $4.83 | $4.44 | -8.1% | +8.1% | Correct so far |
| NXE | Sell | $10.40 | $9.35 | -10.1% | +10.1% | Correct so far |
| OI | Sell | $6.79 | $6.07 | -10.6% | +10.6% | Correct so far |
| NUTX | Buy | $188.41 | $208.79 | +10.8% | +10.8% | Correct so far |
| PENN | Sell | $18.56 | $16.45 | -11.4% | +11.4% | Correct so far |
| LRCX | Sell | $343.84 | $288.11 | -16.2% | +16.2% | Correct so far |
| SRG | Strong Sell | $2.11 | $1.88 | -10.9% | +16.4% | Correct so far |
| OWLT | Sell | $5.81 | $4.74 | -18.4% | +18.4% | Correct so far |
Live LF0 scorecard: The Scorecard | Research Performance dashboard
Past performance does not guarantee future results. Nothing here is investment advice or a recommendation to buy or sell securities. Returns use LF0’s daily-close scorecard methodology.
Leave a Comment